A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Isatuximab (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 25 Jun 2017 Preliminary results from the dose-escalation cohorts and the expansion cohort (n=26; data cut off 8 Nov, 2016), presented at the 22nd Congress of the European Haematology Association
    • 06 Jun 2017 Preliminary results (data cut off 8 Nov, 2016) from the dose-escalation cohorts and from the the first 3 patients of the expansion cohort, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 27 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top